Literature DB >> 17293228

The impact of concurrent granulocyte macrophage-colony stimulating factor on radiation-induced mucositis in head and neck cancer patients: a double-blind placebo-controlled prospective phase III study by Radiation Therapy Oncology Group 9901.

Janice K Ryu1, Suzanne Swann, Francis LeVeque, Charles W Scarantino, Darlene Johnson, Allan Chen, Andre Fortin, JonDavid Pollock, Harold Kim, Kian K Ang.   

Abstract

PURPOSE: Based on early clinical evidence of potential mucosal protection by granulocyte-macrophage colony stimulating factor (GM-CSF), the Radiation Therapy Oncology Group conducted a double-blind, placebo-controlled, randomized study to test the efficacy and safety of GM-CSF in reducing the severity and duration of mucosal injury and pain (mucositis) associated with curative radiotherapy (RT) in head-and-neck cancer patients. METHODS AND MATERIALS: Eligible patients included those with head-and-neck cancer with radiation ports encompassing >50% of oral cavity and/or oropharynx. Standard RT ports were used to cover the primary tumor and regional lymphatics at risk in standard fractionation to 60-70 Gy. Concurrent cisplatin chemotherapy was allowed. Patients were randomized to receive subcutaneous injection of GM-CSF 250 microg/m2 or placebo 3 times a week. Mucosal reaction was assessed during the course of RT using the National Cancer Institute Common Toxicity Criteria and the protocol-specific scoring system.
RESULTS: Between October 2000 and September 2002, 130 patients from 36 institutions were accrued. Nine patients (7%) were excluded from the analysis, 3 as a result of drug unavailability. More than 80% of the patients participated in the quality-of-life endpoint of this study. The GM-CSF did not cause any increase in toxicity compared with placebo. There was no statistically significant difference in the average mean mucositis score in the GM-CSF and placebo arms by a t test (p = 0.4006).
CONCLUSION: This placebo-controlled, randomized study demonstrated no significant effect of GM-CSF given concurrently compared with placebo in reducing the severity or duration of RT-induced mucositis in patients undergoing definitive RT for head-and-neck cancer.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17293228     DOI: 10.1016/j.ijrobp.2006.09.043

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  16 in total

Review 1.  Interventions for preventing oral mucositis for patients with cancer receiving treatment.

Authors:  Helen V Worthington; Jan E Clarkson; Gemma Bryan; Susan Furness; Anne-Marie Glenny; Anne Littlewood; Martin G McCabe; Stefan Meyer; Tasneem Khalid
Journal:  Cochrane Database Syst Rev       Date:  2011-04-13

Review 2.  Antibody-cytokine fusion proteins: applications in cancer therapy.

Authors:  Elizabeth Ortiz-Sánchez; Gustavo Helguera; Tracy R Daniels; Manuel L Penichet
Journal:  Expert Opin Biol Ther       Date:  2008-05       Impact factor: 4.388

Review 3.  Interventions for preventing oral mucositis in patients with cancer receiving treatment: cytokines and growth factors.

Authors:  Philip Riley; Anne-Marie Glenny; Helen V Worthington; Anne Littlewood; Luisa M Fernandez Mauleffinch; Jan E Clarkson; Martin G McCabe
Journal:  Cochrane Database Syst Rev       Date:  2017-11-28

Review 4.  The humanistic burden of head and neck cancer: a systematic literature review.

Authors:  Erika Wissinger; Ingolf Griebsch; Juliane Lungershausen; Michael Byrnes; Karin Travers; Chris L Pashos
Journal:  Pharmacoeconomics       Date:  2014-12       Impact factor: 4.981

5.  Exploratory Factor Analysis of NRG Oncology's University of Washington Quality of Life Questionnaire-RTOG Modification.

Authors:  Stephanie L Pugh; Gwen Wyatt; Raimond K W Wong; Stephen M Sagar; Bevan Yueh; Anurag K Singh; Min Yao; Phuc Felix Nguyen-Tan; Sue S Yom; Francis S Cardinale; Khalil Sultanem; D Ian Hodson; Greg A Krempl; Ariel Chavez; Alexander M Yeh; Deborah W Bruner
Journal:  J Pain Symptom Manage       Date:  2016-11-27       Impact factor: 3.612

6.  The role of granulocyte macrophage colony stimulating factor (GM-CSF) in radiation-induced tumor cell migration.

Authors:  Marta Vilalta; Jourdan Brune; Marjan Rafat; Luis Soto; Edward E Graves
Journal:  Clin Exp Metastasis       Date:  2018-03-13       Impact factor: 5.150

Review 7.  Review of the complications associated with treatment of oropharyngeal cancer: a guide for the dental practitioner.

Authors:  Lena Turner; Muralidhar Mupparapu; Sunday O Akintoye
Journal:  Quintessence Int       Date:  2013-03       Impact factor: 1.677

Review 8.  Systematic review of cytokines and growth factors for the management of oral mucositis in cancer patients.

Authors:  Judith E Raber-Durlacher; Inger von Bültzingslöwen; Richard M Logan; Joanne Bowen; Abdul Rahman Al-Azri; Hele Everaus; Erich Gerber; Jesùs Garcia Gomez; Bo G Pettersson; Yoshihiko Soga; Fred K L Spijkervet; Wim J E Tissing; Joel B Epstein; Sharon Elad; Rajesh V Lalla
Journal:  Support Care Cancer       Date:  2012-09-18       Impact factor: 3.603

Review 9.  Head and neck cancer.

Authors:  Athanassios Argiris; Michalis V Karamouzis; David Raben; Robert L Ferris
Journal:  Lancet       Date:  2008-05-17       Impact factor: 79.321

10.  The impact of concurrent granulocyte-macrophage colony-stimulating factor on quality of life in head and neck cancer patients: results of the randomized, placebo-controlled Radiation Therapy Oncology Group 9901 trial.

Authors:  Karen E Hoffman; Stephanie L Pugh; Jennifer L James; Charles Scarantino; Benjamin Movsas; Richard K Valicenti; Andre Fortin; JonDavid Pollock; Harold Kim; David G Brachman; Lawrence B Berk; Deborah Watkins Bruner; Lisa A Kachnic
Journal:  Qual Life Res       Date:  2014-02-04       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.